Financing ·
Mesoblast Limited reported Ryoncil net revenues of US$36 million for the quarter ended June 30, 2026, and US$115…
MESOMesoblast Ltd
Mesoblast Limited reported Ryoncil net revenues of US$36 million for the quarter ended June 30, 2026, and US$115 million for its first full year post-FDA approval. The company held US$103 million in cash after drawing down an additional US$50 million from a five-year facility to extinguish all maturing debt obligations. Ryoncil registration trials for adults with steroid-refractory acute graft versus host disease have commenced, and the FDA granted Investigational New Drug clearance for a trial in children aged 5-9 years with Duchenne muscular dystrophy. Mesoblast also achieved its target of treating at least 300 patients in the pivotal Phase 3 trial for rexlemestrocel-L in chronic low back pain and received a BLA filing number for an indication related to heart failure. The company operates in the biotechnology industry, developing allogeneic cellular medicines for inflammatory diseases.